Payment overview · 2025
General Payments
$862.91
25 reported records · 10 companies
Healthcare provider profile · identity verified
Jesus M Hernandez, MD
Allopathic & Osteopathic Physicians|General Practice · NEW YORK, NY · NPI 1083750913
Verified facts
What the public records show
CMS Open Payments records show Jesus M Hernandez, MD received $862.91 in general payments during 2025 across 25 reported records.
Novo Nordisk Inc accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $168.28 | 19.5% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $159.99 | 18.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $142.65 | 16.5% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $135.07 | 15.7% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.00 | 14.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.97 | 3.9% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $30.09 | 3.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.26 | 3.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.56 | 2.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.04 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $833.65 | 23 |
| Education | $29.26 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $168.28 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $159.99 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $135.07 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $62.73 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $57.64 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $30.09 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.26 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 109 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 182 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
182 | 41 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
109 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
184 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 483 | 116 |
| Famotidine | Famotidine | 369 | 97 |
| Diclofenac Sodium | Diclofenac Sodium | 367 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 327 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 305 | 78 |
| Gabapentin | Gabapentin | 299 | 64 |
| Baclofen | Baclofen | 239 | 85 |
| Metformin Hcl | Metformin Hcl | 239 | 60 |
| Buspirone Hcl | Buspirone Hcl | 194 | 52 |
| Sucralfate | Sucralfate | 188 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 187 | 48 |
| Jardiance | Empagliflozin | 184 | 37 |
| Linzess | Linaclotide | 182 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 173 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 170 | 37 |
| Meclizine Hcl | Meclizine Hcl | 169 | 41 |
| Lisinopril | Lisinopril | 168 | 36 |
| Omeprazole | Omeprazole | 164 | 40 |
| Carvedilol | Carvedilol | 163 | 36 |
| Meloxicam | Meloxicam | 162 | 54 |
| Montelukast Sodium | Montelukast Sodium | 162 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 145 | 41 |
| Ammonium Lactate | Ammonium Lactate | 144 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 120 | 67 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 116 | 52 |
| Telmisartan | Telmisartan | 116 | 26 |
| Eliquis | Apixaban | 113 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 111 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 31 |
| Memantine Hcl | Memantine Hcl | 110 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 110 | 26 |
| Farxiga | Dapagliflozin Propanediol | 109 | 24 |
| Donepezil Hcl | Donepezil Hcl | 103 | 22 |
| Glimepiride | Glimepiride | 102 | 25 |
| Tradjenta | Linagliptin | 98 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 96 | 13 |
| Losartan Potassium | Losartan Potassium | 95 | 25 |
| Simvastatin | Simvastatin | 91 | 25 |
| Furosemide | Furosemide | 90 | 27 |
| Ezetimibe | Ezetimibe | 79 | 17 |
| Azithromycin | Azithromycin | 76 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 19 |
| Trazodone Hcl | Trazodone Hcl | 73 | 15 |
| Hydrocortisone | Hydrocortisone | 71 | 25 |
| Ibuprofen | Ibuprofen | 70 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 12 |
| Azelastine Hcl | Azelastine Hcl | 68 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 11 |
| Mirtazapine | Mirtazapine | 65 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 65 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 16 |
| Kerendia | Finerenone | 57 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 57 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 14 |
| Mometasone Furoate | Mometasone Furoate | 52 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 40 |
| Finasteride | Finasteride | 47 | 18 |
| Ozempic | Semaglutide | 47 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 46 | suppressed |
| Nabumetone | Nabumetone | 45 | 13 |
| Metformin Hcl Er | Metformin Hcl | 44 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 11 |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Lorazepam | Lorazepam | 41 | 15 |
| Alprazolam | Alprazolam | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 15 |
| Nystatin | Nystatin | 40 | 23 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | suppressed |
| Belsomra | Suvorexant | 37 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 35 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 34 | suppressed |
| Procto-Med Hc | Hydrocortisone | 33 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 29 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Vascepa | Icosapent Ethyl | 29 | suppressed |
| Acarbose | Acarbose | 28 | suppressed |
| Desloratadine | Desloratadine | 27 | 16 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Sulindac | Sulindac | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Proctozone-Hc | Hydrocortisone | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 17 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 14 | 14 |
| Mupirocin | Mupirocin | 14 | 13 |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $862.91 · 25 records | Novo Nordisk Inc | BREZTRI, CREON, FARXIGA, IBSRELA, INGREZZA, LINZESS, LOKELMA, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ozempic, PANZYGA, RELISTOR, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRULANCE, XELJANZ | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error